Evidence map›Paper›PMID 36452073›Full record

ArticlePeerJ2022

Investigating isoform switching in

Mehar Masood, Madahiah Bint E Masood, Noor Us Subah, Maria Shabbir, Rehan Zafar Paracha, Mehak Rafiq

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mehar MasoodSchool of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
Madahiah Bint E MasoodSchool of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
Noor Us SubahSchool of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
Maria ShabbirAtta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Rehan Zafar ParachaSchool of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
Mehak RafiqSchool of Interdisciplinary Engineering and Sciences, National University of Sciences and Technology, Islamabad, Pakistan.
National University of Sciences and Technology · PKNational University of Technology · PKRiphah International University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer is the second leading cause of cancer-related deaths globally, and its prevalence rates are increasing daily. In the past, studies predicting therapeutic drug targets for cancer therapy focused on the assumption that one gene is responsible for producing one protein. Therefore, there is always an immense need to find promising and novel anti-cancer drug targets. Furthermore, proteases have an integral role in cell proliferation and growth because the proteolysis mechanism is an irreversible process that aids in regulating cellular growth during tumorigenesis. Therefore, an inactive rhomboid protease known as iRhom2 encoded by the gene RHBDF2 can be considered an important target for cancer treatment. Speculatively, previous studies on gene expression analysis of RHBDF2 showed heterogenous behaviour during tumorigenesis. Consistent with this, several studies have reported the antagonistic role of iRhom2 in tumorigenesis, Methods: To observe the differences at isoform resolution, the current strategy identified isoform switching in RHBDF2 via differential transcript usage using RNA-seq data during breast cancer initiation and progression. Furthermore, interacting partners were found via correlation and enriched to explain their antagonistic role. Results: Isoform switching was observed at DCIS, grade 2 and grade 3, from canonical to the cub isoform. Neither EGFR nor ERAD was found enriched. However, pathways leading to TACE-dependent EGFR signalling pathways were more observant, specifically MAPK signalling pathways, GPCR signalling pathways, and toll-like receptor pathways. Nevertheless, it was noteworthy that during CTCs, the cub isoform switches back to the canonical isoform, and the proteasomal degradation pathway and cytoplasmic ribosomal protein pathways were significantly enriched. Therefore, it could be inferred that cub isoform functions during cancer initiation in EGFR signalling. In contrast, during metastasis, where invasion is the primary task, the isoform switches back to the canonical isoform.

Indexed as

Breast NeoplasmsCarrier ProteinsCarcinogenesisErbB ReceptorsFemaleHumansIntracellular Signaling Peptides and ProteinsProtein IsoformsCarrier ProteinsErbB ReceptorsIntracellular Signaling Peptides and ProteinsProtein IsoformsRHBDF2 protein, humanBreast cancerEGFRERADiRhom2RHBDF2TACE

Identifiers

PMID36452073
PMCPMC9703992
OpenAlexW4309937192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.